Free Trial
→ The Fed Just Got Kneecapped — Here’s What Happens Next (From Banyan Hill Publishing) (Ad)tc pixel Free GSK Stock Alerts

GSK (GSK) Stock Forecast & Price Target

GSK logo
GBX 1,511 +14.50 (+0.97%)
As of 11:52 AM Eastern
Compare

GSK - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Hold
Based on 4 Analyst Ratings
Sell
1
Hold
2
Buy
1

Based on 4 Wall Street analysts who have issued ratings for GSK in the last 12 months, the stock has a consensus rating of "Hold." Out of the 4 analysts, 1 has given a sell rating, 2 have given a hold rating, and 1 has given a buy rating for GSK.

Consensus Price Target

GBX 1,637.50
According to the 4 analysts' twelve-month price targets for GSK, the average price target is GBX 1,637.50. The highest price target for GSK is GBX 2,100, while the lowest price target for GSK is GBX 1,400. The average price target represents a forecasted upside of 8.37% from the current price of GBX 1,511.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for GSK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for GSK and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GSK Analyst Ratings Over Time

TypeCurrent Forecast
9/22/24 to 9/22/25		1 Month Ago
8/23/24 to 8/23/25		3 Months Ago
6/24/24 to 6/24/25		1 Year Ago
9/23/23 to 9/22/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price TargetGBX 1,637.50GBX 1,612.50GBX 1,862.50GBX 1,805.71
Consensus RatingHoldHoldModerate BuyModerate Buy

GSK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GSK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

GSK Stock vs. The Competition

TypeGSKMedical Companies
Consensus Rating Score
2.00
2.78
Consensus RatingHoldModerate Buy
News Sentiment Rating
Neutral News

See Recent GSK News
Positive News
Export to Excel
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
8/27/2025Shore Capital
1 of 5 stars		 Reiterated RatingBuyGBX 2,100+41.89%
8/4/2025JPMorgan Chase & Co.
2 of 5 stars		 Lower TargetUnderweightGBX 1,460 ➝ GBX 1,400+0.68%
7/31/2025Deutsche Bank Aktiengesellschaft
3 of 5 stars		 Reiterated RatingHoldGBX 1,450+1.29%
7/18/2025Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Reiterated RatingHoldGBX 1,600+17.69%
7/5/2024Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Lower TargetBuyGBX 2,120 ➝ GBX 1,900+24.79%
6/27/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Reiterated RatingBuyGBX 2,100+38.25%
5/7/2024Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Reiterated RatingEqual WeightGBX 1,725-1.96%
9/25/2023Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Boost TargetGBX 1,440 ➝ GBX 1,585+3.39%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 08:24 PM ET.


Should I Buy GSK Stock? GSK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, September 19, 2025. Please send any questions or comments about these GSK pros and cons to contact@marketbeat.com.

GSK
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in GSK plc:

  • GSK plc has received a "Buy" rating from investment analysts, indicating strong confidence in the stock's potential for growth.
  • The current stock price is around GBX 1,447.50, which is significantly lower than the target price set by analysts, suggesting potential for upside.
  • The company has a diverse portfolio of vaccines and medicines, including recent advancements in mRNA-based influenza vaccines, which could drive future revenue growth.
  • GSK plc has a solid market capitalization of £58.41 billion, providing stability and resources for ongoing research and development.
  • Recent quarterly earnings showed a positive EPS, indicating profitability and effective management of resources.

GSK
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in GSK plc for these reasons:

  • Despite the positive ratings, some analysts have issued "Hold" and "Underweight" ratings, suggesting caution among certain investment circles.
  • The stock has experienced fluctuations, with a one-year low of GBX 1,242.50, indicating potential volatility that could concern risk-averse investors.
  • GSK plc has a high debt-to-equity ratio, which may raise concerns about financial leverage and the company's ability to manage its debt effectively.
  • Recent insider transactions show that some executives are selling shares, which could signal a lack of confidence in the company's short-term performance.
  • The company operates in a highly competitive pharmaceutical industry, which can impact market share and profitability.

GSK Forecast - Frequently Asked Questions

According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for GSK is GBX 1,637.50, with a high forecast of GBX 2,100 and a low forecast of GBX 1,400.

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last year. There is currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.

According to analysts, GSK's stock has a predicted upside of 8.37% based on their 12-month stock forecasts.

GSK has been rated by research analysts at Berenberg Bank, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., and Shore Capital in the past 90 days.

Analysts like GSK less than other "medical" companies. The consensus rating for GSK is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how GSK compares to other companies.

Related Companies
Today's Ratings
Top-Rated Stocks
More Ratings Tools

This page (LON:GSK) was last updated on 9/22/2025 by MarketBeat.com Staff
From Our Partners
He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...
The Oxford Club | Sponsoredtc pixel
Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...
Banyan Hill Publishing | Sponsoredtc pixel
Trump’s new nightmare begins
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...
Porter & Company | Sponsoredtc pixel
Prepare for the “Mar-a-Lago Accord” Money Shock
Why Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...
Stansberry Research | Sponsoredtc pixel
Nvidia Times 1,000,000
Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...
Paradigm Press | Sponsoredtc pixel
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsoredtc pixel
The next AI Hype Spike is days away — don’t miss it
On this date, AI could trigger the kind of predictable surge that's already paid out 61%… 158%… and even 382% ...
Brownstone Research | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel